Loading...
ADIL logo

Adial Pharmaceuticals, Inc.NasdaqCM:ADIL Aktienübersicht

Marktkapitalisierung US$15.7m
Aktienkurs
n/a
1Y-31.5%
7D-15.8%
1D1.1%
Wert des Portfolios
​
Siehe

Adial Pharmaceuticals, Inc.

NasdaqCM:ADIL Lagerbericht

Marktkapitalisierung: US$15.7m

Adial Pharmaceuticals (ADIL) Aktienübersicht

Adial Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika zur Behandlung oder Vorbeugung von Suchtkrankheiten und verwandten Störungen konzentriert. Mehr Details

ADIL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit6/6
Dividenden0/6

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

+ 1 mehr Risiko

ADIL Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW437,476 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
437,476 investors already sharing narratives
View all narratives

Adial Pharmaceuticals, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Adial Pharmaceuticals
Historische Aktienkurse
Aktueller AktienkursUS$6.00
52-Wochen-HochUS$10.75
52-Wochen-TiefUS$1.31
Beta1.39
1 Monat Veränderung39.10%
3 Monate Veränderung101.17%
1 Jahr Veränderung-31.49%
3 Jahre Veränderung-91.82%
5 Jahre Veränderung-99.77%
Veränderung seit IPO-99.76%

Aktuelle Nachrichten und Updates

Recent updates

Seeking Alpha • Aug 22

Adial Clinical Trial: A Fluff Or A Win?

Onward Phase III Clinical Trial of Adial Pharmaceutical’s AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the primary end-points were not achieved in. Onward trial confirmed estimates of population with the required genetic marker for AD04 treatment, corroborating addressable market and firming up potential value for strategic partners and shareholders. Path forward has two lanes: additional Phase 3 clinical trial focused on Heavy Drinkers and/or application for regulatory approval in Europe. Fluff or Win? Argument for a AD04 win sits on deep foundation of clinical knowledge in ondansetron compound and its effectiveness in treating alcoholism - confirmed by Onward trial. Adial Pharmaceuticals, Inc. (ADIL) has made considerable progress in developing of a therapeutic compound based on ondansetron, a serotonin antagonist, for treatment of alcoholism. The company recently completed a Phase III clinical trial of its AD04 compound involving 302 patients diagnosed with Alcohol Use Disorder ((AUD)), which is characterized by uncontrolled drinking and preoccupation with alcohol. While the overall results of the trial suggested ADO4 treatment demonstrated a beneficial trend, the data was not statistically significant compared to the control group taking a placebo. That said, a predetermined subset of participants receiving AD04 did remarkably well and the subset data was statistically significant. Our earlier article making an investment case for Adial, described how the company is building on successful work using ondansetron as a safe treatment for severe nausea and vomiting. However, Adial’s AD04 compound is aimed at an underserved market populated by about 30 million adults in the U.S. who suffer from AUD. Only about 7% of diagnosed patients actually get treatment. The rest are left floundering around in detoxification and abstinence programs that often do not work. AUD sufferers miss work, lose jobs, fail in school, and engage in conduct that disrupts family and social relationships. The U.S. Centers for Disease Control and Prevention ((CDC)) estimates the economic cost of alcohol abuse and dependence in the workplace alone is as much as $249 billion each year in the U.S. Clearly the economic and social costs are substantial, providing incentive to introduce a new treatment, if an effective one can be found. When the Onward trial results were announced in late July 2022, traders and shareholders immediately registered their disappointment through a dramatic sell-off of ADIL in the first trading session following the results announcement. The shares gave up 47% of value from the previous day close. Since then, the stock has traded down another 15%. By contrast, Adial leadership took encouragement from the trial results for further study and potentially even applications for commercial approval by U.S. and/or European drug regulators. This article considers whether the recent Onward clinical trial was indeed a fluff or actually a resounding win in the ‘effectiveness’ race to a lucrative market. End-point and Beyond It is worthwhile to step back from the headlines to look at ALL the results from the Onward clinical trial. The study was aimed at determining whether AD04 would bring about a reduction in heavy drinking days among trial participants over a period of six months. The trial compared a predetermined baseline with heavy drinking days in month six as well as a combination of months five and six. A few more details on the trial design and execution are included at the end of this article. More importantly, summary of Onward trial results is shown in the illustration right below. Some data points have not yet been disclosed by the company, including specifics related to the puzzling group of Very Heavy Drinkers. Adial leadership has promised those details after the company’s scientists have had a chance to complete the usual analysis needed to plan the next clinical trial or to apply for regulatory approval. Onward Clinical Trial Results (Crystal Equity Research) When the final report comes available, it will be the data related to the Very Heavy Drinkers that will be most interesting - 112 folks who average ten or more drinks per drinking day and represent 37% of the total trial group. Given that the 63% flip side of the study, the Heavy Drinker group, rang in a statistically significant reduction in heavy drinking days from baseline, it is this smaller clutch of participants that appears to have skewed the results for the overall trial. During a conference call in late July 2022, to discuss the Onward study results, Adial leadership pointed to the fact that among the Very Heavy Drinkers, heavy drinking days were reduced by more than 50% in both the AD04 and the placebo group. Reducing heavy drinking days is certainly a desired effect, but regulatory officials, especially those at the U.S. FDA, prefer therapeutic compounds that deliver a statistically significant impact greater than a placebo group. Scientific Foundation This is not the first time the ondansetron compound produced eyebrow raising results. A study completed in 1994 and supported by Glaxo Canada, found a reduction in drinking among alcohol-dependent male participants after six weeks of treatment with ondansetron. Significant differences were found when participants drinking more than 10 drinks per drinking day were excluded from the analysis, leaving only the heavy drinkers. The trial tested two dose levels for the ondansetron - 0.25 mg and 2.0 mg. The lower ondansetron dose produced the greatest reduction from baseline in the heavy drinker group, delivering almost four times the number of participants showing a clinically meaningful decrease in drinking. There is something about the folks drinking ten or more drinks per drinking day! Fortunately, for Adial shareholders, the company’s Chief Medical Officer, Dr. Bankole Johnson, may already have insight into the Very Heavy Drinker group standing out in the Onward trial as well as the similar group in the much earlier trial sponsored by Glaxo Canada. In 2000, Johnson published a paper on yet another randomized controlled trial of ondansetron among biologically disposed alcoholic patients. This study included 271 participants and divided the participants into two groups based on early- or late onset-alcoholism. Early-onset was defined as developing alcoholism at 25 years or younger and those developing alcoholism after age 25 were categorized as late-onset. Among participants with early-onset alcoholism, ondansetron significantly reduced self-reported drinking compared with placebo. However, in the group with late-onset alcoholism only those taking the placebo had significantly improved drinking outcomes. Johnson’s paper postulated that there could be a difference in the condition of the 5-HT3 (serotonin) transporter in patients due to damage by chronic alcohol consumption. The hypothesis at the time was that reduced 5-HT3 neurotransmission in patients with early-onset compared with late-onset alcoholism could impact 5-HT3 receptors. This ‘blockade’ could account for ondansetron’s differential treatment effectiveness among groups with differences in alcoholism severity. The Onward trial appears to echo messages from previous trials, but it will be up to Adial’s scientists to determine if alcoholism severity has any bearing on Onward trial. The message that is important for investors is that Adial scientific team appears well experienced to handle the Onward trial outcome for shareholder benefit. Next Steps on Path to the U.S. FDA and Europe’s EMA During the conference call held following announcement of the Onward trial results and in comments since then, management has remained stalwart in their confidence in AD04 to bring relief to AUD suffers. The Onward trial showed clear benefit for the Heavy Drinker group. There is a pressing need for a safe and palatable treatment in a population that has few options. Plans are already being formulated to approach regulators with the Onward trial results and next steps. One possibility is that the company’s scientists head directly for regulatory approval. At least some preliminary discussion is possible with the EMA (European Medicines Agency) of the European Union that could guide any application for regulatory approval for Europe. Experience in the European market could be beneficial in then clearing the same regulatory hurdle in the U.S. Alternatively, an additional Phase 3 clinical trial could screen for severity of alcohol consumption as well as the genetic marker. Indeed, the company’s scientists are already well prepared for an additional Phase 3 effort, making it possible to begin enrollment even before the end of the current year. AD04 has already shown effectiveness among the Heavy Drinker group of AUD suffers. Thus, a plan for another AD04 trial focused exclusively on that group is likely to be well received by either U.S. or European regulators. The key factor for investors to consider is that while not achieving the planned overall end points, the Onward trial gave Adial scientists a large body of encouraging information to impart to regulators. Most importantly, no information arose that indicated AD04 is in anyway harmful or counter-productive. None of the Onward clinical trial participants with AUD who took AD04 were made worse off. We expect these points of fact to be prominent in Adial leadership’s conversations with regulators. Capital Resources: Cash Kitty and Quest for Partner Of course, next steps require capital. Many investors may have been expecting a regulatory application before the end of the current year. That goal could have been pushed out beyond the current year and may require additional capital. Adial has disclosed that the Onward trial required approximately $12 million investment. An additional clinical trial focused on Heavy Drinkers would likely involve just over 500 participants, potentially requiring between $20 million to $30 million in additional capital. Adial leadership is surprisingly sanguine about capital requirements. The team admits to early conversations with potential strategic partners in AD04, which could contribute new capital to the relationship. Such a partner could also bring a ready-made distribution network, a capability that Adial has never developed. In the meantime, the company has a tidy nest egg to at least begin an additional clinical trial started up or to submit an application for regulatory approval. Adial recently reported financial results for the second quarter, disclosing cash and equivalents totaled $9.2 million at the end of June 2022. The company used approximately $1.0 million per month to support operations during the first six months of 2022. The cash burn rate is likely to remain at this level if the company goes ahead with another clinical trial. Thus, at the current cash usage rate the company can keep the lights on for at least another nine months as well as support additional AD04 development. Addressable Market Confirmed While the Onward trial put a wrinkle in the timeline to regulatory approval, it also provided data to quantify the addressable market for AD04. This is a data point that is critical for investors. The trial confirmed that one third of AUD population has the genetic marker that suggests AD04 could be an effective treatment. The number of potential patients is remarkable.
Seeking Alpha • Aug 16

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals press release (NASDAQ:ADIL): Q2 GAAP EPS of -$0.16 beats by $0.01. As of June 30,2022, cash and cash equivalents were $9.2 million as compared to $6.1 million as of December 31, 2021, which the Company believes provides sufficient runway to advance ongoing regulatory and partnering activities related to AD04, as well as advancement of its Purnovate platform. Shares +5% PM.
Seeking Alpha • Jun 21

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

I last reported on Adial 8 months ago - the micro-cap is developing a micro-formulation of Ondansetron - a treatment for nausea and sickness - to treat alcohol use disorder. A 24-week Phase 3 trial is underway in Europe and Scandinavia with an endpoint of reduction in Heavy Drinking Days and total alcohol consumption. Adial is targeting approval in Europe and the US - where it has submitted for Fast Track status. Europe looks a likelier approval shot owing to FDA's stricter trial endpoint. The company's market cap is just $51m and share count 18m. Shareholder dilution is likely - to secure funds for trials and marketing, if approved - as is an acquisition. I still see significant upside potential with Adial and its AUD treatment AD04, based on the EMA approval catalyst, which may arrive next year, but there are a lot of risks and imponderables.

Aktionärsrenditen

ADILUS PharmaceuticalsUS Markt
7D-15.8%-4.0%-2.2%
1Y-31.5%43.7%13.1%

Rendite im Vergleich zur Industrie: ADIL unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 43.7% erzielte.

Rendite vs. Markt: ADIL hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 13.1 erzielte.

Preisvolatilität

Is ADIL's price volatile compared to industry and market?
ADIL volatility
ADIL Average Weekly Movement15.0%
Pharmaceuticals Industry Average Movement8.8%
Market Average Movement6.9%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.9%

Stabiler Aktienkurs: Der Aktienkurs von ADIL war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: ADILDie wöchentliche Volatilität (15%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
20105Cary Claibornewww.adial.com

Adial Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika zur Behandlung oder Vorbeugung von Suchterkrankungen und damit verbundenen Störungen konzentriert. Das führende Produkt des Unternehmens ist AD04, ein Serotonin-3-Antagonist, der sich in klinischen Phase-3-Studien zur Behandlung von Alkoholabhängigkeit befindet. Darüber hinaus ist das Unternehmen an der Entwicklung von Arzneimittelkandidaten zur nicht-opioiden Schmerzlinderung und für andere Krankheiten und Störungen beteiligt.

Adial Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Adial Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
ADIL grundlegende Statistiken
MarktanteilUS$15.74m
Gewinn(TTM)-US$57.80m
Umsatz(TTM)n/a
0.0x
Kurs-Umsatz-Verhältnis
-0.3x
Kurs-Gewinn-Verhältnis

Ist ADIL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ADIL Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$0
Kosten der EinnahmenUS$0
BruttogewinnUS$0
Sonstige AusgabenUS$57.80m
Gewinn-US$57.80m

Zuletzt gemeldete Gewinne

Jun 30, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-22.01
Bruttomarge0.00%
Nettogewinnspanne0.00%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich ADIL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/09/11 07:23
Aktienkurs zum Tagesende2026/09/10 00:00
Gewinne2026/06/30
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Adial Pharmaceuticals, Inc. wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
James MolloyAlliance Global Partners
Brian Kemp DolliverBrookline Capital Markets
Elemer PirosLucid Capital Markets